Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.

Future oncology (London, England) - 1 Jun 2026

Bryce Alan Haruo, Nash Paige, Roessler Anne, Mandair Divneet

Abstract excerpt

Rucaparib (RUBRACAⓇ) is the first FDA-approved poly (ADP-ribose) polymerase (PARP) inhibitor for men with BRCA mutation-associated metastatic castration-resistant prostate cancer (mCRPC). Rucaparib's efficacy in patients with mCRPC associated with DNA damage repair (DDR) deficiency was demonstrated in the TRITON2 and TRITON3 trials. In TRITON2, rucaparib demonstrated meaningful antitumor activity in men with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Indoles

Share to Mutation

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prostatic Neoplasms, Castration-Resistant

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 42312474
DOI: 10.1080/14796694.2026.2681674
PMCID: PMC13374775

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.PMID 42312474Read ↗

Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analysesSemantic proximity Read ↗

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic LandscapeSemantic proximity Read ↗

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring aBRCA1orBRCA2Gene AlterationSemantic proximity Read ↗

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.Semantic proximity Read ↗

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudySemantic proximity Read ↗

[Poly(ADP-ribose) polymerase (PARP-)inhibitors as genetically based precision therapy in metastatic castration-resistent prostate cancer (mCRPC)].Semantic proximity Read ↗

PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence.Semantic proximity Read ↗

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.Semantic proximity Read ↗

Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.Semantic proximity Read ↗

PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCASemantic proximity Read ↗

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging TrendsSemantic proximity Read ↗

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.